...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS
【24h】

A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS

机译：使用候选疟疾疫苗RTS，S / AS02A和MVA-CS进行初免-加强免疫的临床试验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Heterologous prime-boost immunisation with RTS,S/AS02A and the poxvirus MVA-CS was evaluated in 18 healthy malaria-naive subjects in Oxford. Both priming with RTS,S and boosting MVA-CS, and the reverse, were found to be safe and well tolerated. T cell responses as measured by IFN-gamma ex vivo ELISPOT were induced, but the responses were low to moderate in both groups, with heterologous boosting yielding only small increments in T cell immunogenicity and no increased antibody response. Protection against 3D7 Plasmodium falciparum sporozoite challenge 4 weeks after the final vaccination was equal for both regimens at 33% (95% C.I. 4.3-77.7%), with one subject remaining fully protected on rechallenge at 5 months.
机译：在牛津大学的18位未接受疟疾的健康受试者中，评估了用RTS，S / AS02A和痘病毒MVA-CS进行的异源初免-加强免疫。发现RTS，S和增强MVA-CS均是安全的，并且耐受性良好。通过IFN-γ离体ELISPOT测量的T细胞应答被诱导，但是两组应答均低至中度，异源加强仅产生T细胞免疫原性的小增量，而抗体应答没有增加。最终疫苗接种后第4周，针对3D7恶性疟原虫子孢子攻击的保护作用在两种方案下均相等，均为33％（95％C.I. 4.3-77.7％），其中一名受试者在接受再攻击后5个月仍受到完全保护。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号